Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Therapy with an SGLT2 Inhibitor and a GLP-1 RA on Sirt1 Expression in Type 2 Diabetes
jRCT1031250503Recruiting
- Sponsor
- Grants-in-Aid for Scientific Research
- Start
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of dapagliflozin and semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Grants-in-Aid for Scientific Research. Primary endpoint: Change in Sirt1 gene expression in peripheral blood. Started Nov 2025; status: recruiting.
02
Drugs
dapagliflozinsemaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1031250503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250503.